Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evinacumab for Homozygous Familial Hypercholesterolemia.

The New England journal of medicine - 20 Aug 2020

Raal Frederick J, Rosenson Robert S, Reeskamp Laurens F, Hovingh G Kees, Kastelein John J P, Rubba Paolo, Ali Shazia, Banerjee Poulabi, Chan Kuo-Chen, Gipe Daniel A, Khilla Nagwa, Pordy Robert, Weinreich David M, Yancopoulos George D, Zhang Yi, Gaudet Daniel

Abstract excerpt

BACKGROUND: Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) cholesterol. This disorder is associated with genetic variants that result in virtually absent (null-null) or impaired (non-null) LDL-receptor activity. Loss-of-function variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiopoietin-Like Protein 3
Share to Angiopoietin-like Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticholesteremic Agents

Share to Double-Blind Method

Share to Hyperlipoproteinemia Type II

Share to Infusions, Intravenous

Share to Least-Squares Analysis

Share to Receptors, LDL

Source

Identifiers

PMID: 32813947
DOI: 10.1056/NEJMoa2004215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evinacumab for Homozygous Familial Hypercholesterolemia.PMID 32813947Read ↗

Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study.Semantic proximity Read ↗

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.Semantic proximity Read ↗

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.Semantic proximity Read ↗

Evidence for improved survival with treatment of homozygous familial hypercholesterolemiaSemantic proximity Read ↗

Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary.Semantic proximity Read ↗

ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.Semantic proximity Read ↗

Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.Semantic proximity Read ↗

How ANGPTL3 Inhibition Will Help Our Clinical Practice?Semantic proximity Read ↗

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.Semantic proximity Read ↗

Evolocumab in patients with homozygous familial hypercholesterolemia in India.Semantic proximity Read ↗

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.Semantic proximity Read ↗

Selective Targeting of Angiopoietin-like 3 (ANGPTL3) with Vupanorsen for the Treatment of Patients with Familial Partial Lipodystrophy (FPLD): Results of a Proof-of-Concept StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.